CT-388 Research for Obesity
An evidence-based overview of research examining CT-388 in the context of obesity. This page synthesizes findings from peer-reviewed literature.
Research Summary
The published CT-388 Phase 1 trial (NCT04838405) showed mean weight loss of 4.7-8.0% vs 0.5% placebo at 4 weeks. A widely reported ~18.8% placebo-adjusted weight loss at 24 weeks comes from an unpublished Phase 1 extension (press release, not peer-reviewed). The dual GLP-1/GIP mechanism is the same class as the FDA-approved tirzepatide (Mounjaro/Zepbound). Phase 2 obesity trials (NCT06525935) are completed with results pending.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. CT-388 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.